A case of indolent systemic mastocytosis responding to treatment with Avapritinib
Key Clinical Message Low dose Avapritinib is a new medication that is a potential treatment option not just for advanced systemic mastocytosis, but also for the indolent form.
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
Wiley
2024-02-01
|
| coleção: | Clinical Case Reports |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1002/ccr3.8500 |